Chengdu Easton - Public Comps and Valuation Multiples

Chengdu Easton Overview

About Chengdu Easton

Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.

Founded

2009

HQ

Employees

n/a

Website

eastonpharma.cn

Sectors

Drug Development & Therapeutics
Small Molecules
BioTech
DeepTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$738M

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Chengdu Easton Financials

Chengdu Easton has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Chengdu Easton achieved revenue of $154M and an EBITDA of $43.9M.

Chengdu Easton expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Chengdu Easton valuation multiples based on analyst estimates

Chengdu Easton P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$154M	n/a	XXX	XXX	XXX
Gross Profit	$121M	$134M	XXX	XXX	XXX
Gross Margin	79%	NaN%	XXX	XXX	XXX
EBITDA	$43.9M	n/a	XXX	XXX	XXX
EBITDA Margin	28%	NaN%	XXX	XXX	XXX
Net Profit	$32.0M	$34.0M	XXX	XXX	XXX
Net Margin	21%	NaN%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Chengdu Easton Stock Performance

As of April 15, 2025, Chengdu Easton's stock price is CNY 37 (or $5).

Chengdu Easton has current market cap of CNY 6.6B (or $909M), and EV of CNY 5.4B (or $738M).

See Chengdu Easton trading valuation data

Chengdu Easton Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$738M	$909M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Chengdu Easton Valuation Multiples

As of April 15, 2025, Chengdu Easton has market cap of $909M and EV of $738M.

Chengdu Easton's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Chengdu Easton's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Chengdu Easton and 10K+ public comps

Chengdu Easton Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$738M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	XXX	XXX
P/E	n/a	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Chengdu Easton Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Chengdu Easton Valuation Multiples

Chengdu Easton's NTM/LTM revenue growth is n/a

Chengdu Easton's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Chengdu Easton's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Chengdu Easton's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Chengdu Easton and other 10K+ public comps

Chengdu Easton Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	n/a	XXX	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	n/a	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	29%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	2%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	21%	XXX	XXX	XXX	XXX
Opex to Revenue	61%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry